

unnecessary. Rather than imposing excessive requirements that will force substantial costs on the parties, the Commission should have allowed the merger of Amoco and BP to proceed with antitrust relief limited to terminaling as well as the Ohio and the Pittsburgh, Pennsylvania wholesaling situation.

I therefore dissent from the aspects of this matter dealing with gasoline wholesaling in the southeastern United States markets identified in Paragraph 15 of the proposed complaint.

[FR Doc. 99-2073 Filed 1-28-99; 8:45 am]

BILLING CODE 6750-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.  
**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

*Ms. Nellie Briggs-Brown, Rush-Presbyterian-St. Luke's Medical Center:* Based on the report of an investigation conducted by Rush-Presbyterian-St. Luke's Medical Center dated December 3, 1997, ORI finds that Ms. Briggs Brown, former employee, Department of Neurology, engaged in scientific misconduct in clinical research supported by two National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) grants.

Specifically, Ms. Briggs-Brown (1) falsified seven monthly screening logs for a NINDS funded study involving stroke victims (Randomized Trial of Org 10172 in Acute Ischemic Stroke Treatment) and submitted the same logs with altered dates on multiple occasions to the University of Iowa Coordinating Center; and (2) falsified several Human Investigation Committee research approval forms.

None of the questioned data has been included in publications.

ORI has implemented the following administrative actions for the three (3) year period beginning January 25, 1999:

(1) Ms. Briggs-Brown is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) Any institution that submits an application for PHS support for a

research project on which Ms. Briggs-Brown's participation is proposed or which uses her in any capacity on PHS supported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. Briggs-Brown's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

**FOR FURTHER INFORMATION CONTACT:** Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

**Chris B. Pascal,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 99-2158 Filed 1-28-99; 8:45 am]

BILLING CODE 4160-17-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

*Robert J. Thackeray, R.N., M.P.H., University of Pittsburgh:* Based on an investigation report prepared by the University of Pittsburgh, dated June 24, 1998, and information obtained by ORI during its oversight review, ORI found that Mr. Thackeray, former program coordinator, Multi center AIDS Cohort Study (MACS), Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, engaged in scientific misconduct in research supported by the National Institutes of Health (NIH). The Pitt Men's Study is a component of the MACS funded by a cooperative agreement with the National Institute of Allergy and Infectious Diseases (NIAID), NIH.

Specifically, Mr. Thackeray falsified and/or fabricated research data that he recorded from various tests that he was responsible for conducting on subjects enrolled in the MACS.

Mr. Thackeray falsified and/or fabricated data for five subjects and reported that data on the "Neurological Assessment Form 10" and on the "Instrumental Activities of Daily Living Scale" questionnaire.

The fabricated and/or falsified research data were not compiled elsewhere and were not included in any publications.

Mr. Thackeray has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning January 19, 1999:

(1) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which his participation is proposed or which uses him in any capacity on PHS supported research, or that submits a report of PHS-funded research in which he is involved, must concurrently submit a plan for supervision of his duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Mr. Thackeray's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

**FOR FURTHER INFORMATION CONTACT:** Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

**Chris B. Pascal,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 99-2157 Filed 1-28-99; 8:45 am]

BILLING CODE 4160-17-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Health Care Policy and Research

#### Notice of Meetings

In accordance with section 10(d) of the Federal Advisory Committee Act (5 U.S.C. Appendix 2) announcement is made of the following subcommittees scheduled to meet during the month of February 1999:

*Name:* Health Care Quality and Effectiveness Research.

*Date and Time:* February 9, 1999, 8:00 a.m.

*Place:* Bethesda Hyatt, 1 Bethesda Metro Center, Bethesda, Maryland 20814.

Open February 9, 8:30 a.m. to 8:45 a.m. Closed for remainder of meeting.

*Purpose:* To review and evaluate grant applications.

*Name:* Health Systems Research.

*Date and Time:* February 18, 1999, 9:30 a.m.